GLP-1 Therapy for Type 2 Diabetes: Clinical Update 2026

GLP-1 receptor agonists have become central to type 2 diabetes management over the past decade. The combination of glycemic efficacy, weight loss, and cardiovascular risk reduction has elevated GLP-1 agonists to first-line or early-line status in major clinical guidelines.

This post provides a 2026 clinical update on GLP-1 therapy for type 2 diabetes — covering the evidence base, current guidelines, and practical prescribing considerations.

GLP-1 receptor agonists produce clinically meaningful reductions in HbA1c:

• Semaglutide (Ozempic): HbA1c reduction of 1.5–1.8% in clinical trials
• Tirzepatide (Mounjaro): HbA1c reduction of 2.0–2.3% in the SURPASS trials — the largest HbA1c reductions seen with any non-insulin diabetes medication
• Liraglutide (Victoza): HbA1c reduction of 1.0–1.5%

These reductions are achieved with a low risk of hypoglycemia (because GLP-1 agonists stimulate insulin secretion in a glucose-dependent manner).

Weight loss is a significant benefit of GLP-1 therapy in T2D patients, who are often overweight or obese:

• Semaglutide: 4–6 kg average weight loss in T2D trials
• Tirzepatide: 7–12 kg average weight loss in SURPASS trials
• Liraglutide: 2–4 kg average weight loss

Weight loss in T2D patients improves insulin sensitivity, reduces cardiovascular risk, and can lead to remission of diabetes in some patients.

Multiple large cardiovascular outcomes trials have demonstrated cardiovascular risk reduction with GLP-1 agonists in T2D patients with established cardiovascular disease:

• LEADER (liraglutide): 13% reduction in MACE
• SUSTAIN-6 (semaglutide): 26% reduction in MACE
• REWIND (dulaglutide): 12% reduction in MACE

These trials established GLP-1 agonists as cardiovascular risk reduction agents, not just glucose-lowering drugs.

GLP-1 agonists have also shown renal protective effects in T2D patients with chronic kidney disease:

• FLOW trial (semaglutide): 24% reduction in kidney disease progression
• AWARD-7 (dulaglutide): Reduced decline in eGFR

The American Diabetes Association's 2026 Standards of Care recommend GLP-1 receptor agonists as preferred agents for T2D patients with:

• Established cardiovascular disease or high cardiovascular risk
• Chronic kidney disease
• Obesity or overweight (BMI ≥25)
• Need for weight loss alongside glycemic control

For patients with T2D and obesity, the ADA recommends considering GLP-1 agonists at doses approved for weight management (semaglutide 2.4 mg, tirzepatide 10–15 mg) rather than lower diabetes doses.

The American Association of Clinical Endocrinology guidelines similarly recommend GLP-1 agonists as first-line or early-line therapy for T2D patients with cardiovascular risk factors or obesity.

For T2D patients who cannot access branded GLP-1 therapies, compounded preparations offer an access pathway. Key considerations:

Clinical rationale: Document the reason for using a compounded preparation (cost, access, specific formulation need).

Dose equivalence: Compounded preparations should be prescribed at doses equivalent to the branded product's therapeutic doses.

Monitoring: T2D patients on GLP-1 therapy require monitoring of HbA1c, blood glucose, and renal function.

Insulin adjustment: T2D patients on insulin who start GLP-1 therapy may need insulin dose reduction to avoid hypoglycemia.

When starting a GLP-1 agonist in a patient on insulin:

• Reduce basal insulin by 10–20% at initiation
• Monitor blood glucose closely during titration
• Adjust insulin based on glucose monitoring

Most GLP-1 agonists can be used in patients with mild to moderate chronic kidney disease. Semaglutide and liraglutide do not require dose adjustment for renal impairment. Tirzepatide does not require dose adjustment for mild to moderate CKD.

The combination of GLP-1 agonists and SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) is increasingly used in T2D patients with cardiovascular or renal disease. The combination provides complementary mechanisms and additive cardiovascular and renal protection.

Request portal access →

This content is for informational and educational purposes only. It does not constitute medical advice. Prescribers should review current guidelines and use clinical judgment.